Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner
Author:
Funder
Fonden til Lægevidenskabens Fremme
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Hematology
Link
http://link.springer.com/article/10.1007/s11239-017-1512-2/fulltext.html
Reference20 articles.
1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
2. Ageno W, Eikelboom J, Lip GY (2016) Dabigatran in clinical practice: contemporary overview of the evidence. Int J Cardiol 220:417–428
3. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N (2007) In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98:155–162
4. Wong PC, Jiang X (2010) Apixaban, a direct factor xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor viia, xia and thrombin. Thromb Haemost 104:302–310
5. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 103:879–887
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Ex Vivo Antiplatelet Effects of Oral Anticoagulants;Journal of Cardiovascular Development and Disease;2024-03-31
2. The study of platelet aggregation using a microtiter plate reader ‒ methodological considerations;Pharmacological Reports;2024-03-05
3. Targeting PAR4 to Reduce Atherosclerosis;Arteriosclerosis, Thrombosis, and Vascular Biology;2023-11
4. Diabetes- versus smoking-related thrombo-inflammation in peripheral artery disease;Cardiovascular Diabetology;2023-09-21
5. Antiplatelet drugs: Potential therapeutic options for the management of neurodegenerative diseases;Medicinal Research Reviews;2023-05-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3